A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata

Kerry-Ann L Dillon, Kerry-Ann L Dillon

Abstract

Alopecia areata (AA) is a chronic, immune-mediated form of nonscarring alopecia that is multifactorial and results in localized patches. It is often described as a self-limiting condition that results in the spontaneous regrowth of hair in most cases. However, this regrowth may take several months or years to occur in some patients, leading to the development of psychoemotional trauma in those that are affected. Although several therapies for AA have been developed and tested, there is no specific treatment that has been approved, leading to the availability of many off-label conventional treatment options, with very limited responses. More recently, with the advancement of pre-clinical and genetic studies, a greater understanding of the pathomechanisms involved in the development of AA has been uncovered. This has resulted in the introduction of targeted therapies that use small molecules to block specific pathways involved in AA pathophysiology. As such, the use of janus kinase (JAK) inhibitors for treatment of AA has emerged. JAK inhibitors block the T-cell mediated inflammatory response thought to be the driving factor behind AA pathogenesis, by inhibiting the janus kinase (JAK) signal transducer and activator of transcription (STAT) signaling pathway, leading to a reversal of hair loss in AA patients. Thus, in an effort to demonstrate the efficacy of JAK inhibitors in the treatment of AA, several studies have been published within recent years. However, the question remains, "Are JAK inhibitors effective and safe in the management of Alopecia Areata?". This review aims to provide a comprehensive report on the role, efficacy, and outcomes of using JAK inhibitors in the treatment of AA. To competently answer the research question highlighted, the most recent, quality articles published over a 10-15-year period were sourced using PubMed, NCBI, Research gate, Medline, Cochrane Central Register of Controlled Trials, EMBASE and Google scholar. The literature search was primarily focused on randomized controlled trials (RCTs); however, in the absence of such, only the most recently published case reports, case series, clinical trials and open-label studies published to date were included.

Keywords: JAK-STAT signaling pathway; baricitinib; janus kinase; ruxolitinib; tofacitinib.

Conflict of interest statement

The author has no conflicts of interest to declare for this work.

© 2021 Dillon.

Figures

Figure 1
Figure 1
The Janus kinase signal transducer and activator of transcription (JAK-STAT) signaling pathway.
Figure 2
Figure 2
Role of JAKis in the JAK-STAT pathway.

References

    1. Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic jak inhibitors in dermatology. Front Immunol. 2019;10:2847. doi:10.3389/fimmu.2019.02847
    1. Johnson R, Roh E, Saavedra A, Wolff K. Fitzpatrick’s Colour Atlas and Synopsis of Clinical Dermatology. 8th ed. New York: McGraw-Hill Edu; 2017.
    1. Oakley A. Alopecia Areata. DermNet NZ; 2015. Available from: . Accessed February3, 2020.
    1. Trueb R, Dutra H, Dias M. A comment on jak inhibitors for treatment of alopecia areata. Int J Trichology. 2018;10(5):193–197. doi:10.4103/ijt.ijt_62_18
    1. Damsky W, King B. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi:10.1016/j.jaad.2016.12.005
    1. Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Develop Ther. 2018;12:2323–2335. doi:10.2147/DDDT.S172638
    1. Guo H, Cheng Y, Shapiro J, McElwee K. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol. 2015;11(12):1335–1351. doi:10.1586/1744666X.2015.1085306
    1. Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Invest Dermatol Symposium Proceedings. 2003;8(2):188–194. doi:10.1046/j.1087-0024.2003.00807.x
    1. Kranseler J, Sidbury R. Alopecia areata: update on management. Indian J Paediatr Dermatol. 2017;18(4):261–266. doi:10.4103/ijpd.IJPD_80_17
    1. Anzai A, Wang E, Lee E, Aoki V, Christiano A. Pathomechanisms of immune-mediated alopecia. Int Immunol. 2019;31(7):439–447. doi:10.1093/intimm/dxz039
    1. D’Ovidio R. Alopecia areata: news on diagnosis, pathogenesis and treatment. G Ital Dermatol Venereol. 2014;149(1):25–45.
    1. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by jak inhibition. Nat Med. 2014;20(9):1043–1049. doi:10.1038/nm.3645
    1. McElwee K, Freyschmidt-Paul P, Hoffman R, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/Cd25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124(5):947–957. doi:10.1111/j.0022-202X.2005.23692.x
    1. Trueb R, Dias M. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2017;54:68–87. doi:10.1007/s12016-017-8620-9
    1. Darwin E, Hirt P, Fertig R, Doliner B, Delcanto G, Jimenez J. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51–60. doi:10.4103/ijt.ijt_99_17
    1. Petukhova L, Christiano A. Functional interpretation of genome-wide association study evidence in alopecia areata. J Invest Dermatol. 2016;136(1):314–317. doi:10.1038/JID.2015.402
    1. Betz R, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966. doi:10.1038/ncomms6966
    1. Manolache L, Benea V. Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol. 2007;21(7):921–928. doi:10.1111/j.1468-3083.2006.02106.x
    1. Gulec T, Tanriverdi N, Duru C, Saray Y, Akcali C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol. 2004;43(5):352–356. doi:10.1111/j.1365-4632.2004.02028.x
    1. Habif T. Clinical Dermatology. A Guide to Diagnosis and Therapy. 6th ed. Netherlands: Elsevier Inc; 2016.
    1. Korta D, Christiano A, Berfield W, et al. Alopecia areata is a medical disease. J Am Acad Dermatol. 2018;78(4):832–834. doi:10.1016/j.jaad.2017.09.011
    1. Ghanizadeh A, Ayoobzadehshirazi A. A review of psychiatric disorders comorbidities in patients with alopecia areata. Int J Trichology. 2014;6(1):2–4. doi:10.4103/0974-7753.136746
    1. Fricke A, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403. doi:10.2147/CCID.S53985
    1. Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J, Macbeth A. Interventions for alopecia areata. Cochrane Database of Systematic Reviews. 2008;CD004413. doi:10.1002/14651858.CD004413.pub2
    1. Hammerschmidt M, Brenner F. Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol. 2014;89(5):729–734. doi:10.1590/abd1806-4841.20142869
    1. Vano-Galvan S, Hermosa-Gelbard A, Sanchez-Neila N, et al. Treatment of Recalcitrant Adult Alopecia Areata Universalis with Oral Azathioprine. J Am Acad Dermatol. 2016;74(5):1007–1008. doi:10.1016/j.jaad.2015.12.055
    1. Wang E, Sallee B, Tejeda C, Christiano A. Montagna symposium 2017- janus kinase inhibitors for treatment of alopecia areata. J Invest Dermatol. 2018;138(9):1911–1966. doi:10.1016/j.jid.2018.05.027
    1. Fragoulis G, McInnes I, Siebert S. JAK-inhibitors: new players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology. 2019;58(1):43–54. doi:10.1093/rheumatology/key276
    1. Aittomaki S, Pesu M. Therapeutic targeting of the JAK/STAT pathway. Basic Clin Pharmacol Toxicol. 2013;114(1):18–23. doi:10.1111/bcpt.12164
    1. O’Shea J, Plenge R. JAKs and STATs in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550. doi:10.1016/j.immuni.2012.03.014
    1. Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34:1594–1609. doi:10.1007/s12325-017-0542-7
    1. Craiglow B, King B. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990. doi:10.1038/jid.2014.260
    1. Anzengruber F, Maul J, Kamarachev J, Trueb R, French L, Navarini A. Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol. 2016;8(1):102–106. doi:10.1159/000445182
    1. Dhayalan A, King B. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA. 2016;152(4):492–493.
    1. Ferreira S, Scheinberg M, Steiner D, Steiner T, Bedin G, Ferreira R. Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report. Case Rep Dermatol. 2016;8(3):262–266. doi:10.1159/000450848
    1. Gupta A, Carviel J, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016;30(8):1373–1378. doi:10.1111/jdv.13598
    1. Jabbari A, Nguyen N, Cerise J, et al. Treatment of alopecia areata with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642–643. doi:10.1111/exd.13060
    1. Kennedy Crispin M, Ko J, Craiglow B, et al. Safety and efficacy of the jak inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. doi:10.1172/jci.insight.89776
    1. Bayart C, DeNiro K, Brichta L, Craiglow B, Sidbury R. Topical janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–170. doi:10.1016/j.jaad.2017.03.024
    1. Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol. 2017;76(4):754–755. doi:10.1016/j.jaad.2016.11.038
    1. Craiglow B, Liu L, King B. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29–32. doi:10.1016/j.jaad.2016.09.006
    1. Erduran F, Adisen E, Aksakal A. Excellent response to tofacitinib in a patient with alopecia universalis. Acta Dermatovenerol APA. 2017;26:47–49. doi:10.15570/actaapa.2017.15
    1. Ibrahim O, Bayart C, Hogan S, Piliang M, Bergfeld W. Treatment of alopecia areata with tofacitinib. JAMA. 2017;153(6):600–602.
    1. Kim B, Kim H. Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment. Singapore Med J. 2017;58(5):279–280. doi:10.11622/smedj.2017039
    1. Liu L, Craiglow B, King B, Dai F. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–28. doi:10.1016/j.jaad.2016.09.007
    1. Mrowietz U, Gerdes S, Glaser R, Schroder O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. 2017;97(2):283–284. doi:10.2340/00015555-2491
    1. Park H, Kim M, Lee J, Huh C, Kwon O, Cho S. Oral tofacitinib monotherapy in Korean patients with refractory moderate-severe alopecia areata: a Case Series. J Am Acad Dermatol. 2017;77(5):978–980. doi:10.1016/j.jaad.2017.06.027
    1. Salman A, Sarac G, Ergun T. Alopecia universalis unresponsive to treatment with tofacitinib: report of a case with brief review of the literature. Dermatol Online J. 2017;23(7):15.
    1. Scheinberg M, de Lucena Couto Océa RA, Cruz BA, Ferreira SB. Brazilian experience of the treatment of alopecia universalis with the novel antirheumatic therapy tofacitinib: a case series. Rheumatol Ther. 2017;4(2):503–508. doi:10.1007/s40744-017-0069-z
    1. Strazzulla LC, Avila L, Sicco K, Shapiro J. Image Gallery: treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections. Br J Dermatol. 2017;176(6):e125. doi:10.1111/bjd.15483
    1. Jabbari A, Sansarcq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch type alopecia areata, totalis and universalis. J Invest Dermatol. 2018;138(7):1539–1545. doi:10.1016/j.jid.2018.01.032
    1. Liu L, Craiglow B, King B. Tofacitinib 2% ointment, a topical janus kinase inhibitor for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403–404. doi:10.1016/j.jaad.2017.10.043
    1. Patel N, Oussedik E, Grammenos A, Pichardo-Geisinger R. A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg. 2018;22(4):439–442. doi:10.1177/1203475418760512
    1. Shivanna C, Shenoy C, Priya R. Tofacitinib (selective janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients. Int J Trichology. 2018;10(3):103–107. doi:10.4103/ijt.ijt_21_18
    1. Akdogan N, Ersoy-Evans S, Dogan S, Atakan N. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. Dermatol Ther. 2019;32(6):e13118. doi:10.1111/dth.13118
    1. Ferreira S, Ferreira R, Scheinberg M. An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature. Clin Case Rep. 2019;7(12):2539–2542. doi:10.1002/ccr3.2484
    1. Jerjen R, Meah N, Trindade de Carvalho L, Wall D, Eisman S, Sinclair R. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study. Pediatr Dermatol. 2021;38(1):103–108. doi:10.1111/pde.14422
    1. Dincer Rota D, Emeksiz MAC, Erdogan FG, Yildirim D. Experience with oral tofacitinib in severe alopecia areata with different clinical responses. J Cosmet Dermatol. 2021;00:1–8.
    1. Higgins E, Al Shehri T, McAleer M, Feighery C, Lilic D, Irvine A. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis cause by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–553. doi:10.1016/j.jaci.2014.12.1867
    1. Pieri L, Guglielmelli P, Vannucchi A. Roxulitinib-induced reversal of alopecia universalis in a patient with essential thrombocytopenia. Am J Hematol. 2015;90(1):82–83. doi:10.1002/ajh.23871
    1. Craiglow B, Tavares D, King B. Topical ruxolitinib for the treatment of alopecia universalis. JAMA. 2016;152(4):490–491.
    1. Harris J, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata. J Am Acad Dermatol. 2016;74(2):370–371. doi:10.1016/j.jaad.2015.09.073
    1. Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair-growth in patients with moderate-severe alopecia areata. JCI Insight. 2016;1(15):e89790. doi:10.1172/jci.insight.89790
    1. Deeb M, Beach R. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg. 2017;21(6):562–563. doi:10.1177/1203475417716363
    1. Vandiver A, Girardi N, Alhariri J, Garza L. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol. 2017;56(8):833–835. doi:10.1111/ijd.13598
    1. Ramot Y, Zlotogorski A. Complete regrowth of beard with roxulitinib in an alopecia universalis patient. Skin Appendage Disord. 2018;4(2):122–124. doi:10.1159/000479722
    1. Liu L, King B. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566–568. doi:10.1016/j.jaad.2018.08.040
    1. Olsen EA, Kornacki D, Sun K, Hordinsky MK. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled Phase 2 study. J Am Acad Dermatol. 2020;82(2):412–419. doi:10.1016/j.jaad.2019.10.016
    1. Fetter T, Cuevas Rios G, Niebel D, Bieber T, Wenzel J. Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib. Acta Derm Venereol. 2020;100(10):adv00144. doi:10.2340/00015555-3481
    1. Peterson D, Vesely M. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. J Am Acad Dermatol. 2020;6(4):257–259.
    1. Jabbari A, Zhenpeng D, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–355. doi:10.1016/j.ebiom.2015.02.015
    1. Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. J Am Acad Dermatol. 2019;5(10):892–894.
    1. Shi J, Chen X, McGee R, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51(12):1644–1654. doi:10.1177/0091270010389469
    1. Carfagna M, Cannady E, Ryan T, et al. Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl: CD)rats. Regul Toxicol Pharmacol. 2018;92:458–471. doi:10.1016/j.yrtph.2017.11.020
    1. Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–856. doi:10.1111/jdv.15489
    1. Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):192–201. doi:10.1111/jdv.15937
    1. Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. The Lancet. 2019;393(10169):318–319. doi:10.1016/S0140-6736(18)32987-8
    1. GlobalData Healthcare. Can JAK inhibitors penetrate the alopecia areata market effectively. GlobalData Healthcare, Pharmaceutical Technology; 2019. Available from: . Accessed June19, 2020.
    1. Xconomy. With FDA’s Eye on JAK Drugs, Concert Pharma Moves One Ahead for Hair Loss; 2019. Available from: . Accessed June19, 2020.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit